While ER, PR and Ki-67 are quantified routinely by image analysis during the clinical workup of breast cancers and are reported as the percentage of positive cells in the clinical pathology report, the clinical assessment of HER2 expression is based on a categorical 0, 1+, 2+ and 3+ scale. This evidence concerns the gene ESR1 and breast carcinoma.